2024-510663-34-00招募中2 期
An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infection.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 11
- 试验地点
- 6
- 主要终点
- Clearance (CL)
研究概览
简要总结
To characterise single and multiple dose to steady state pharmacokinetics of IV zanamivir in hospitalised neonates and infants under 6 months of age with influenza infection
入排标准
- 年龄范围
- 0 years 至 17 years（0-17 Years）
- 接受健康志愿者
- 是
入选标准
- •Age. Neonates and infants who are aged less than 6 months (corrected age) at the time of the informed consent signed by legally acceptable representative (LAR) of minors. Preterm neonates and infants will be eligible for inclusion but must have reached Post-Menstrual Age (PMA) of at least 28 weeks.
- •Participants who are hospitalised with influenza infection, confirmed by a positive rapid molecular diagnostic test for influenza, or a local quantitative RT-PCR test and who must have a potential for improvement. Subjects with negative rapid molecular test result suspected of having influenza can be enrolled following confirmatory testing by quantitative RT-PCR.
- •Weight. Body weight ≥1kg.
- •Sex. Male or female.
- •Informed Consent Legally acceptable representative (LAR) of minors are willing and able to give written informed consent to participate in the study (or included as permitted by local regulatory authorities, IECs or local laws).
排除标准
- •Participants who are known or suspected to be hypersensitive to any component of the study medication.
- •Participants who, in the judgment of the investigator, are unlikely to complete the course of treatment due to their current disease process.
- •Liver function: • Subjects who meet the following criteria at Baseline: ALT ≥3xULN with Bilirubin ≥2xULN or Isolated bilirubin ≥ 2xULN and >50% direct bilirubin or ALT ≥5xULN Inclusion of subjects with liver function tests that fall outside these criteria must be discussed and agreed with the medical monitor. • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of benign conditions such as Gilbert's syndrome). Inclusion of subjects with neonatal hyperbilirubinaemia may be considered if appropriately managed according to local guidelines and must be discussed with the medical monitor.
- •Participants who require concurrent therapy with another anti influenza drug.
- •Participants who have participated in a study using an investigational drug within 30 days prior to Baseline.
- •Child in care (CiC), as defined below: • A child who has been placed under the control or protection of an agency, organisation, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. • The definition of a CiC can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The definition of a CiC does not include a child who is adopted or has an appointed legal guardian.
- •Patients undergoing treatment by Extracorporeal membrane oxygenation (ECMO) or hemofiltration.
- •Participants who are positive for SARS-CoV-2, as determined by a diagnostic test, at screening.
结局指标
主要结局
Clearance (CL)
Clearance (CL)
Area under the serum concentration-time curve (AUC)
Area under the serum concentration-time curve (AUC)
Maximum serum concentration (Cmax)
Maximum serum concentration (Cmax)
Terminal half-life (t1/2)
Terminal half-life (t1/2)
次要结局
未报告次要终点
研究者
EU GSK Clinical Trials Call Center
Scientific
Glaxosmithkline Research & Development Limited
研究点 (6)
Loading locations...
相似试验
已完成
1 期
A Phase 1, Multicentre, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single IV Dose of Rezafungin Acetate in Paediatric Subjects from Birth to <18 Years of Age, Receiving Systemic Antifungals as Prophylaxis for Invasive Fungal Infection or to Treat a Suspected or Confirmed Fungal InfectionFungal infections2022-501985-23-00Mundipharma Research Limited, Mundipharma Research Limited24
招募中
2 期
A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER (The ADJUNCT Study)PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER2025-521489-80-00Medica Scientia Innovation Research S.L.25
已完成
1 期
扎那米韦静脉注射液在健康人群的药代动力学研究人类流行性感冒CTR2015084524
已完成
1 期
Study in Participants With Normal Kidney Function and Reduced Kidney Function to Test How Kidney Function Can Change What Happens to Obeldesivir in the BodyRenal Impairment2023-504780-17-00Gilead Sciences Inc.10
招募中
3 期
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapyAcute myeloid leukemia2025-522979-29-00Fundacion PETHEMA350